Showing posts with label Singapore Pharmaceutical Industry. Show all posts
Showing posts with label Singapore Pharmaceutical Industry. Show all posts

Wednesday, July 27, 2022

COVID 19 Impact on Singapore’s Pharmaceutical Market: Ken Research

 Buy Now

Market Overview

Singapore Pharmaceutical Market can be permeated by the availability of best-in-class infrastructure, integrated hubs for pharmaceutical manufacture and research, access to regional markets, and trained labor. The income of the Singapore pharmaceutical market increased between the period of 2012 and 2017. AbbVie, Pfizer, Ferring Pharmaceuticals, and many more top biomedical corporations have chosen Singapore as their worldwide production headquarters. The pharmaceutical market in Singapore grew at a single-digit CAGR between 2012 and 2017. Singapore is one of Southeast Asia's most technologically advanced and integrated centers for pharmaceutical manufacture and research. Singapore has established two biomedical hubs: Tuas Biomedical Park and Biopolis. While the Tuas Biomedical Park is largely focused on pharmaceutical manufacturing and production, on the other hand Biopolis fosters collaboration between public and private research institutions.

Singapore Pharmaceutical Market

Report Overview

According to the research report, “Singapore Pharmaceutical Market Outlook to 2022 – by Prescription & OTC Drugs and by Patented & Generic Drugs” expresses that multinational corporations (MNCs) dominate the market, which is fragmented, with a strong emphasis on R&D operations. As of 2017, there were 54 pharmaceutical companies, and 5,500 medications were registered. GSK, Novartis, Roche, Pfizer, Bayer, AstraZeneca, Abbott, Baxter, Maccine, and others are significant international corporations. The development of inventive over-the-counter, generic, prescription and consumer health medications has increased, according to the pharmaceutical industry. Product range, distribution network, technology, and R&D expenditure are important competition criteria.

Request for Sample Report: - https://www.kenresearch.com/sample-report.php?Frmdetails=MTQ5NjY4

By Prescription & OTC Drugs

In 2017, the majority of the pharmaceutical market's sales in Singapore were of prescription medications. The remaining portion of the earnings came from over-the-counter medicines. The prevalence of chronic conditions like diabetes, cancer, and others has further fueled prescription medication sales, which can be ascribed to the rise in prescription use. Due to Singapore's growing trend of self-medication, the sale of OTC medications has been increasing. Most antibiotics are sold over-the-counter. One of the OTC market areas with the fastest growth is vitamins and dietary supplements.

By Patented & Generic Drugs

The largest portion of the revenue in Singapore's prescription drug market in 2017 came from patented medications. The remainder of the revenue has been made up of generic medications. Seek IP protection has encouraged worldwide businesses to establish production facilities and secure patent protection for their pharmaceuticals, APIs, and manufacturing techniques. It is also encouraged by the availability of cutting-edge infrastructure and significant financial investments in research initiatives. Drugs for oncology and infectious disorders are among them.

Future Outlook

Because everyone in Singapore has access to health insurance and has access to top-notch biomedical research facilities, the country's pharmaceutical market is anticipated to increase at a single-digit CAGR between the period of 2017 and 2018.

The nation will continue to draw international investment due to its world-class manufacturing and research facilities. In order to expand its research and development (R&D) capabilities in Singapore, Japan's Chugai Pharmaceutical, which runs satellite labs throughout Asia, aims to invest USD 355 million by 2021. The industry will see an increase in technological advancements to promote automation and boost productivity. For instance, GSK has been a leader in the field of continuous manufacturing, which replaces batch production with continuous addition and removal of inputs and products. At their manufacturing facilities across the nation, major international pharma manufacturers increase output and develop automation.

For More Info on the Research Report, Click on the below link: -

Singapore Pharmaceutical Market Size

Related Report by Ken Research: -

Indonesia Pharmacy Retail Market Outlook to 2025 By Market Structure (Organized & Unorganized); By Region (West Java , East Java , Central Java , Jakarta , North Sumatra & Others); By Product Categories (Prescribed, OTC, Non-Pharmaceutical Products & Medical Equipment); By Therapeutic Areas; and By Product Type (Patented & Generic Drugs)

Contact Us: -
Ken Research
Ankur Gupta, Head Marketing & Communications
Support@kenresearch.com
+91-9015378249

Follow Us

LinkedIn | Facebook | Twitter | YouTube

Wednesday, June 27, 2018

Singapore Pharmaceutical Market is driven by Public Private Partnerships in R&D and Expansion of Multinational Companies in Local Market: Ken Research

World Class manufacturing facilities, skilled workforce, expansion of product portfolio by major pharmaceutical companies, government grants and tax incentives were the key factors driving growth in Singapore pharmaceutical Market.

Singapore Pharmaceutical Market can be characterized by the presence of best-in-class infrastructure, integrated and advanced hubs for pharmaceutical manufacturing and research and access to regional markets and skilled workforce. The government has invested in forming competitive clusters to attract research, clinical trials, and manufacturing companies in the pharmaceutical sector. This includes developing infrastructure such as Biopolis, and the Tuas Biomedical Park, tax breaks and business incentives and funding of public-sector research institutes.
Research and Development forms an essential part of the pharmaceutical industry. Various multinational companies have been involved in private-public partnerships in Singapore, particularly with R&D and clinical trials. The Contract Research Organization (CRO) market in Asia grew at a rate of 20% in 2017, with Singapore’s A*STAR leading some of the clinical growth. Few established R&D partnerships in Singapore include Roche’s (Basel, Switzerland) Singapore Hub for Translational Medicine, GlaxoSmithKline’s (Brentford, UK) Academic Centre of Excellence, and Bayer Healthcare’s (Leverkusen, Germany) partnership with the Singapore National Eye Center (SNEC).

Singapore currently hosts more than 50 international biomedical science companies, including GlaxoSmithKline, Takeda, Pfizer, Novartis and Roche. As a result of Singapore’s robust infrastructure, intellectual property (IP) protection, access to regional markets and skilled workforce, many leading biomedical companies have selected Singapore as their global manufacturing base for a wide range of products including Active Pharmaceutical Ingredients, drug products and biologics drug substances.

Singapore pharmaceutical market will continue to incline at a positive growth rate owing to increased investment in biopharmaceutical manufacturing, and growing Contract Research Organization market  

The report titled “Singapore Pharmaceutical Market Outlook to 2022 - by Prescription & OTC Drugs and by Patented & Generic Drugs” by Ken Research suggested a growth at a CAGR of 6.8% in revenue in Singapore Pharmaceutical Market by 2022. Singapore Pharmaceutical market can be characterized by the presence of best-in-class infrastructure, integrated and advanced hubs for pharmaceutical manufacturing and research & access to regional markets and skilled workforce. Many leading biomedical companies such as AbbVie, Pfizer, Ferring Pharmaceuticals and others have selected Singapore as their global manufacturing base

For more information on the research report, refer to below link:

Related Reports by Ken Research

Currently all patented drugs are imported for local consumption. Widely imported patented drugs include high-value specialty drugs for oncology and diabetes management.


Majority pharmaceutical companies are located in West Java and Jakarta due to favorable tax incentives, well developed infrastructure and greater access to medicinal herbs.

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
0124-4230204

Tuesday, June 26, 2018

Singapore Pharmaceutical Market is expected to Reach USD 1.8 Billion by 2022: Ken Research

                    Singapore Pharmaceutical Market engages over 50 top global biomedical science firms and 30 public research institutes which aim to create a biomedical ecosystem that concentrates infrastructure and technology

                    Singapore has developed 2 biomedical hubs namely Biopolis and Tuas Biomedical Park which facilitate the cooperation between public sector research centers with private labs and pharmaceutical manufacturing and production.

                    The market is fragmented with multinational companies dominating the space with major focus on research & development activities. Major multinational companies include GSK, Novartis, Roche, Pfizer, Bayer, AstraZeneca, Abbott, Baxter, Maccine and others.

Singapore Pharmaceutical Industry will be led by increased investment in biopharmaceutical manufacturing and growing research & development activities in the space. The best in class research and manufacturing infrastructure will continue to attract foreign investment in the country. For instance, Japan’s Chugai Pharmaceutical, which operates satellite labs throughout Asia, has plans to invest USD 355 million by 2021, to accelerate its research and development (R&D) capabilities in Singapore. Further, Zuellig Pharma who launched its first innovation centre, Zuellig Health Solutions (ZHS), in Singapore in 2017, plans to invest over SGD 50 million over the next five years. Mundipharma plans to start commercial production of antiseptics at its new plant in Singapore in 2019. Apart from innovation in modern medicine, increased demand for pharmaceutical drugs in Asia, which is driven by growing middle class and an ageing population, has increased the market demand for non-essential and therapeutic treatments. The demand for dietary supplements will increase in order to fulfill the nutrition requirement of the people in their busy lifestyle. Due to the prevalence of chronic diseases such as diabetes, heart diseases and others and aging population, revenue from the prescription drugs will continue to occupy the larger share.

The ongoing success of large pharmaceutical companies and increase in biopharmaceutical startups across the country is creating a growing number of new pharma job opportunities in Singapore. Big global drug makers ramp up output and advance automation at their production sites across the country. The opening of new sites such as AbbVie’s biologics manufacturing facility and the ramp up of others including Amgen and Novartis will augment the manufacturing activities of these firms.

The industry will witness a rise in development of technology to support automation and increase productivity. For instance, GSK has been pioneering a technology called continuous manufacturing where instead of making products in batches, materials are constantly added and products removed Emerging Contract Research Organization market, increasing number of mergers & acquisitions coupled with elevating prevalence of chronic and lifestyle diseases will propel Singapore pharmaceutical market revenue in future.

Ken Research in its latest study, “Singapore Pharmaceutical Market Outlook to 2022 - by Prescription & OTC Drugs and by Patented & Generic Drugs”, suggests that demand for pharmaceutical products in the market will continue to grow in Singapore owing to growing public-private partnerships in R&D and clinical trials and expansion of multinational companies in the space.

Key Topics Covered in the Report:
Pharmaceutical Market Size Singapore
OTC Drugs Market Singapore
Prescription Drugs Market Singapore
Patented Drugs Market Singapore
Generics Drug Market Singapore
Singapore Pharmaceutical Industry
Regulations Medicine Market Singapore
New Drug Approvals in Singapore
Value Chain Pharmaceutical Singapore
Competition Singapore Pharmaceutical
Pharmaceutical Manufacturers Singapore
Singapore Pharmaceutical Future
Forecast Revenue Pharmaceutical Singapore
Contract Research Organization Market Singapore
Number of Clinical Trials Singapore
Vitamins and Dietary Supplements Market Singapore
Vitamin Dietary Supplements Market Singapore
CRO Market Regulations Singapore
CRO Market Growth Singapore
Singapore Biopharmaceutical Market
Number of Pharmaceutical Companies Singapore

For more information on the research report, refer to below link:

Products Covered
Prescribed Drugs, OTC Drugs, Biopharmaceuticals, Generic Drugs, Branded Medicine, Vitamin and Dietary Supplements, Drug approvals, Drug Pipeline

Companies Covered:
Haw Par Corporation, Beacon Pharmaceuticals, GSK, Singapore, Roche, Singapore, AstraZeneca, Singapore, Lonza, Singapore, Baxter, Singapore, Abbott, Singapore, MSD, Singapore, Sunward Pharmaceutical, Poli Medical, Union Chemicals and Pharmaceuticals Pte Ltd, Schwabe Pharma Asia Pacific Pte Ltd, and Chemical Company of Malaysia Berhad

Related Reports by Ken Research

Currently all patented drugs are imported for local consumption. Widely imported patented drugs include high-value specialty drugs for oncology and diabetes management.


Majority pharmaceutical companies are located in West Java and Jakarta due to favorable tax incentives, well developed infrastructure and greater access to medicinal herbs.

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
0124-4230204